The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths.
Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create new therapeutic options for cancer patients.
BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential:
- Acute myeloid leukaemia (AML)
- Advanced non-small-cell lung cancer (NSCLC)
- Triple negative breast cancer (TNBC)
The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules.
BerGenBio intends to develop its drug candidates itself and through strategic partnerships in multiple indications, and retains all options for the future commercialization of its products.